Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 15/20 | 0.64 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.55 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.53 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.53 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21839636 | 1.00 | NT5E (0.64) | NT5EDNPH1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL30394795 | 1.00 | NT5E (0.64) | NT5EDNPH1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL30394683 | 0.89 | NT5E (0.79) | NT5EDNPH1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21839730 | 0.89 | NT5E (0.79) | NT5EDNPH1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL23907506 | 0.89 | NT5E (0.61) | NT5EDNPH1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21839552 | 0.88 | NT5E (0.68) | NT5EDNPH1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21839549 | 0.88 | NT5E (0.68) | NT5EDNPH1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL30394507 | 0.88 | NT5E (0.68) | NT5EDNPH1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21839513 | 0.87 | NT5E (0.67) | NT5EDNPH1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21839512 | 0.87 | NT5E (0.67) | NT5EDNPH1PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885DNPH1 297/4885PRKAG1 438/4885 |
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | NT5E 5/4885DNPH1 1090/4885PRKAG1 637/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885DNPH1 297/4885PRKAG1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.